|By PR Newswire||
|March 21, 2014 05:19 PM EDT||
LONDON, March 21, 2014 /PRNewswire/ --
The US markets saw a positive sentiment on Thursday, March 20, 2014, with the NASDAQ Composite closing at 4,319.29, up 0.27%, the Dow Jones Industrial Average ending the session at 16,331.05, up 0.67% and the S&P 500 edging 0.60% higher to finish the trading session at 1,872.01. During the session, gains in the Information Technology, Financials, and Telecommunication Services sectors positively impacted the broader market. A number of stocks saw large movements, including ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Centrais Eletricas Brasileiras S.A. (NYSE: EBR), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) and Sinovac Biotech Ltd (NASDAQ: SVA). Free technical research on ZIOP, EBR, CPRX and SVA can be downloaded upon signing up at:
On Thursday, shares in ZIOPHARM Oncology Inc. ended the session at $5.42, up 11.75%, hitting a new 52-week high of $5.58. A total of 3.42 million shares were traded as compared to a three months average volume of 1.05 million shares. During the session, the stock traded between $5.15 and $5.58. ZIOPHARM Oncology Inc.'s shares have advanced 26.05% in the last one month, 35.50% in the previous three months and 24.88% on YTD basis. The S&P 500 Health Care Sector Index mapped a loss of 0.02% during the trading session and charted up 0.77% in the last one month. Further, the stock is trading at a Relative Strength Index (RSI) of 63.24 and trading above its 50-day and 200-day moving averages of $4.40 and $3.59, respectively. Sign up today to read free research on ZIOP at:
Shares in Centrais Eletricas Brasileiras SA edged 4.64% higher, finishing Thursday's session at $2.48. The stock fluctuated between $2.36 and $2.65 during the session with a trading volume of 2.93 million shares as compared to a three months average volume of 1.10 million shares. Shares in Centrais Eletricas Brasileiras SA have gained 15.89% in the previous three trading sessions and 20.39% in the last one month, while the same has fallen by 4.25% on YTD basis. The S&P 500 Utilities Sector Index mapped a gain of 0.10% during the trading session and charted up 6.11% in previous three months. Furthermore, the stock is trading at an RSI of 63.02 and trading above its 50-day and 200-day moving averages of $2.20 and $2.43, respectively. Sign up today to read free research on EBR at:
Shares in Catalyst Pharmaceutical Partners Inc. closed Thursday's session at $2.39, which is 6.22% higher than the previous day's closing price of $2.25. A total of 2.84 million shares were traded as compared to a three months average volume of 0.91 million shares. The stock oscillated between $2.21 and $2.50 during the trading session. Shares in Catalyst Pharmaceutical Partners Inc. have surged 11.68% in the previous three trading sessions, 27.13% in the last three months and 22.56% on YTD basis. The S&P 500 Health Care Sector Index mapped a loss of 0.02% during the trading session and charted up 7.91% in the previous three months. Moreover, the stock is trading at an RSI of 59.70 and trading above its 50-day and 200-day moving averages of $2.05 and $1.82, respectively. Sign up today to read free research on CPRX at:
Sinovac Biotech Ltd's stock finished Thursday's session at $8.07, up 17.13%, recording a new 52-week high of $8.09. A total of 4.88 million shares were traded which is above the three months average volume of 0.34 million shares. The stock vacillated between $7.16 and $8.09 during the session and traded at a PE ratio of 67.25. Sinovac Biotech Ltd's shares have rallied 21.54% in the last one month and 31.86% on YTD basis. The S&P 500 Health Care Sector Index mapped a loss of 0.02% during the trading session and charted up 0.78% in the previous three trading sessions. Additionally, the stock is trading at an RSI of 61.32 and trading above its 50-day and 200-day moving averages of $6.53 and $5.56, respectively. Sign up today to read free research on SVA at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
You have great SaaS business app ideas. You want to turn your idea quickly into a functional and engaging proof of concept. You need to be able to modify it to meet customers' needs, and you need to deliver a complete and secure SaaS application. How could you achieve all the above and yet avoid unforeseen IT requirements that add unnecessary cost and complexity? You also want your app to be responsive in any device at any time. In his session at 19th Cloud Expo, Mark Allen, General Manager of...
Jan. 18, 2017 07:30 PM EST Reads: 3,125
Jan. 18, 2017 06:15 PM EST Reads: 4,182
Jan. 18, 2017 05:30 PM EST Reads: 4,858
Jan. 18, 2017 05:00 PM EST Reads: 1,149
Jan. 18, 2017 05:00 PM EST Reads: 221
Jan. 18, 2017 04:45 PM EST Reads: 4,879
Jan. 18, 2017 04:45 PM EST Reads: 5,364
Jan. 18, 2017 04:45 PM EST Reads: 4,563
Jan. 18, 2017 04:30 PM EST Reads: 4,746
Jan. 18, 2017 03:45 PM EST Reads: 4,695
Jan. 18, 2017 03:30 PM EST Reads: 3,678
Jan. 18, 2017 03:30 PM EST Reads: 3,400
Jan. 18, 2017 02:45 PM EST Reads: 1,587
Jan. 18, 2017 02:15 PM EST Reads: 980
When you focus on a journey from up-close, you look at your own technical and cultural history and how you changed it for the benefit of the customer. This was our starting point: too many integration issues, 13 SWP days and very long cycles. It was evident that in this fast-paced industry we could no longer afford this reality. We needed something that would take us beyond reducing the development lifecycles, CI and Agile methodologies. We made a fundamental difference, even changed our culture...
Jan. 18, 2017 02:00 PM EST Reads: 929